A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma
{{output}}
BRAF/MEK targeted therapies and immune checkpoint inhibition have dramatically improved disease control and survival of patients with advanced melanoma. However, most patients do not have durable benefit from either of these therapies. BRAF targeted therapy of... ...